Utrophin gene promoter (UTRN promoter)

The **utrophin gene promoter** (UTRN promoter) refers to the regulatory DNA sequences upstream of the utrophin (UTRN) gene that control the initiation of gene transcription. The UTRN gene encodes utrophin, a cytoskeletal protein with roles similar to dystrophin, and is of significant interest in therapeutic strategies for Duchenne muscular dystrophy (DMD), as upregulating utrophin can compensate for the absence of dystrophin[1][5][7]. Two main promoter regions, A and B, drive the expression of different utrophin isoforms; promoter A is mainly active in neurons and glial cells, while promoter B shows activity predominantly in vascular and ependymal tissues[1][6]. Activating the UTRN promoter via genome-editing technologies (e.g., CRISPR/dCas9 fused to transcriptional activators) or transcription factor modulation (such as inhibition of Engrailed-1, EN1) has emerged as a promising method to increase utrophin levels in muscle, offering a potential treatment for DMD[3][4][7]. The promoter itself does not encode protein and is not a classical therapeutic target like a receptor or enzyme, but it is a major focus of drug development as a gene-regulatory element. Its safety profile and disease associations are primarily linked to the efficacy and specificity of strategies designed to modulate its activity. The UTRN gene and its promoter may also play a role as a biomarker and potential therapeutic target in other conditions, such as certain cancers, through modulation of utrophin expression[2].

Other names

UTRN promoterUtrophin (A and B) promotersUtrophin gene promoter region

Transcriptional upregulation via promoter activation (e.g., by CRISPR-based activators, knockdown of transcriptional repressors such as EN1, or small molecules that activate promoter-specific pathways)